O
ALXN

OrbiMed’s Alexion Pharmaceuticals ALXN Stock Holding History

OrbiMed’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-150,000
Closed -$22.9M – 182
2021
Q1 		$22.9M Buy
+150,000
New +$23.2M 0.21% 93
2020
Q4 		– Sell
-125,000
Closed -$14.3M – 168
2020
Q3 		$14.3M Buy
125,000
+25,000
+25% +$2.7M 0.18% 100
2020
Q2 		$11.2M Buy
+100,000
New +$10.6M 0.16% 94
2018
Q3 		– Sell
-70,000
Closed -$8.69M – 165
2018
Q2 		$8.69M Buy
70,000
+20,000
+40% +$2.34M 0.1% 114
2018
Q1 		$5.57M Buy
+50,000
New +$5.98M 0.07% 118
2017
Q2 		– Sell
-50,000
Closed -$6.06M – 150
2017
Q1 		$6.06M Sell
50,000
-50,000
-50% -$6.45M 0.07% 110
2016
Q4 		$12.2M Buy
+100,000
New +$12.2M 0.16% 83
2013
Q4 		– Sell
-100,000
Closed -$11.6M – 138
2013
Q3 		$11.6M Buy
+100,000
New +$11M 0.21% 68

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

OrbiMed's ALXN Position: Q3 2021 in Review

OrbiMed sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 150,900 shares — an estimated $27.7M sold.

OrbiMed first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $511M in Q3 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • OrbiMed reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • OrbiMed sold 150,900 Alexion Pharmaceuticals shares in Q3 2021, an estimated $27.7M.
  • OrbiMed first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • OrbiMed's Alexion Pharmaceuticals position peaked at $511M in Q3 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.